Last updated: September 24, 2026
Certolizumab pegol, marketed as Cimzia by UCB, is a mature TNF inhibitor with approximately €2 billion in annual sales and a differentiated pregnancy and placental-transfer profile. Its commercial trajectory depends on maintaining share in rheumatoid arthritis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis as the product moves beyond biologic exclusivity and faces increasing biosimilar and therapeutic competition.
UCB has extended Cimzia's lifecycle through additional indications, dosing options, prefilled delivery systems, global commercialization, and positioning for women of childbearing potential. The product's main financial risk is not immediate demand erosion, but gradual price and volume pressure from competing TNF inhibitors, newer immunology biologics, and potential certolizumab biosimilars.
What is certolizumab pegol and how does Cimzia work?
Certolizumab pegol is a PEGylated antigen-binding fragment of a monoclonal antibody that targets tumor necrosis factor alpha, or TNF-alpha. Unlike full-length IgG antibodies, certolizumab pegol does not contain an Fc region. UCB commercializes it under the Cimzia brand.
The product is administered by subcutaneous injection. Approved dosing varies by indication and may include every-two-week or every-four-week maintenance schedules after an induction regimen.
| Attribute |
Cimzia |
| Active ingredient |
Certolizumab pegol |
| Drug class |
TNF inhibitor |
| Molecular format |
PEGylated Fab' fragment |
| Manufacturer |
UCB |
| Initial U.S. approval |
2008 |
| Main U.S. indications |
Crohn's disease, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis |
| Administration |
Subcutaneous injection |
| Principal differentiation |
Fc-free structure and limited placental transfer |
| Primary markets |
United States, Europe, Japan and other international markets |
The absence of an Fc region limits active transport across the placenta through the neonatal Fc receptor. That characteristic has supported Cimzia's use in patients who require TNF inhibition during pregnancy, although treatment decisions remain indication-specific and physician-directed. UCB has also promoted the product's pregnancy data through the CRIB and CRADLE pharmacokinetic studies (Mariette et al., 2018; Clowse et al., 2017).
How has Cimzia revenue developed?
Cimzia has remained one of UCB's largest products. Public UCB reporting indicates that sales increased from roughly €1.6 billion in 2019 to approximately €2.0 billion in 2023.
| Fiscal year |
Approximate Cimzia sales |
Direction |
| 2019 |
€1.6 billion |
Growth |
| 2020 |
€1.8 billion |
Growth |
| 2021 |
€1.9 billion |
Growth |
| 2022 |
Approximately €2.0 billion |
Stable to modest growth |
| 2023 |
Approximately €2.0 billion |
Mature-product growth |
Sources: UCB annual reports for fiscal years 2019 through 2023.
The product's estimated 2019-to-2023 revenue compound annual growth rate was approximately 5% to 6%. This performance is stronger than the trajectory normally expected from a mature TNF inhibitor, but the rate of expansion has moderated as Cimzia approaches broad market maturity.
UCB's broader portfolio has reduced the company's dependence on Cimzia. Bimzelx, Briviact, Fintepla, and other products have become increasingly important contributors to growth. Cimzia remains strategically important because it generates a large recurring cash flow base, but its share of UCB's total revenue is declining as newer medicines expand.
Which regions contribute most to Cimzia revenue?
The United States is the largest commercial market for Cimzia and the main source of both revenue and pricing exposure. Europe provides a substantial second market, but European prices are lower and subject to national reimbursement controls. Japan and other international markets contribute additional volume, often through local reimbursement and distribution arrangements.
The U.S. market has supported Cimzia's revenue through:
- Higher biologic net prices than most European markets.
- Broad use across several immune-mediated diseases.
- Employer and commercial insurance coverage.
- Demand from patients who require or prefer a pregnancy-compatible TNF inhibitor.
- Continued use after inadequate response to conventional therapies.
European revenue is more exposed to tendering, reference pricing, national health technology assessments, and biosimilar substitution policies.
What are Cimzia's main market-growth drivers?
Cimzia's commercial performance rests on disease breadth, physician familiarity, and a differentiated use case rather than on rapid expansion of the overall TNF inhibitor class.
Pregnancy and reproductive-health positioning
Cimzia has a favorable pharmacokinetic profile for pregnancy-related treatment decisions. The molecule's limited placental transfer has allowed UCB to differentiate it from full-length IgG1 TNF inhibitors. This positioning is particularly relevant in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and inflammatory bowel disease.
The advantage is strongest when a patient requires ongoing TNF inhibition and the physician seeks to reduce fetal exposure. It does not eliminate competition because clinicians may use other TNF inhibitors before conception, during selected periods of pregnancy, or when clinical response is superior.
Multiple approved indications
Cimzia's indication breadth gives UCB several prescribing channels:
| Disease area |
Commercial role |
| Rheumatoid arthritis |
Established base with extensive TNF competition |
| Crohn's disease |
High-value specialty segment with biologic persistence |
| Psoriatic arthritis |
Growth market with competition from IL-17, IL-23 and JAK therapies |
| Axial spondyloarthritis |
Strong fit for long-term biologic treatment |
| Plaque psoriasis |
Competitive market with newer, higher-efficacy biologics |
| Pregnancy-associated treatment |
Cross-indication differentiation |
Cimzia benefits from switching opportunities when patients fail conventional disease-modifying antirheumatic drugs or need a different biologic mechanism. Its growth is constrained when treatment guidelines favor IL-17, IL-23, JAK, or other targeted therapies over TNF inhibition.
Delivery-system development
UCB has commercialized prefilled syringes and autoinjector options. Device improvements support adherence and reduce administration friction, but they generally provide lifecycle support rather than create durable product exclusivity. Device patents can delay substitution at the presentation level, but they do not prevent substitution through alternative certolizumab formulations or competing biologics.
How does Cimzia compare with competing biologics?
Cimzia competes in a mature TNF market and in broader specialty immunology markets.
| Product |
Company |
Mechanism |
Main competitive issue for Cimzia |
| Humira |
AbbVie and biosimilar manufacturers |
TNF inhibitor |
Large installed base and extensive biosimilar price pressure |
| Enbrel |
Amgen/Pfizer |
TNF inhibitor |
Long commercial history and payer familiarity |
| Remicade |
Janssen and biosimilar manufacturers |
TNF inhibitor |
Intravenous and subcutaneous competition |
| Simponi |
Janssen |
TNF inhibitor |
Monthly dosing and established rheumatology use |
| Stelara |
Johnson & Johnson and biosimilar entrants |
IL-12/23 inhibitor |
Strong IBD and psoriasis positioning |
| Skyrizi |
AbbVie |
IL-23 inhibitor |
High efficacy and growing IBD use |
| Tremfya |
Johnson & Johnson |
IL-23 inhibitor |
Psoriasis, PsA and IBD expansion |
| Cosentyx |
Novartis |
IL-17 inhibitor |
Strong axial spondyloarthritis and psoriasis competition |
| Rinvoq |
AbbVie |
JAK inhibitor |
Oral administration and high efficacy, subject to safety restrictions |
| Bimzelx |
UCB |
IL-17A/F inhibitor |
Internal UCB competition and portfolio substitution |
UCB's Bimzelx is strategically significant. It gives UCB exposure to a newer immunology class with stronger growth potential, but it also creates a portfolio-management issue. Some patients and prescribers may migrate from Cimzia to Bimzelx, especially in plaque psoriasis and psoriatic arthritis. UCB can retain the prescriber relationship, but a portion of internal sales may shift from the mature product to the growth product.
When does Cimzia lose exclusivity?
Cimzia's U.S. biologic exclusivity expired in 2020, based on the FDA's 12-year reference-product exclusivity period beginning with the 2008 approval. Biologic exclusivity is separate from patent protection and does not itself determine the date of commercial biosimilar entry.
| Protection category |
Position |
| U.S. reference-product exclusivity |
Expired in 2020 |
| Patent protection |
Depends on individual composition, formulation, process and device claims |
| Orange Book listing |
Not applicable to the biologic reference product in the small-molecule Orange Book framework |
| Biosimilar pathway |
Available after reference-product exclusivity and subject to FDA approval |
| European supplementary protection |
Country-specific and dependent on granted patents and SPC rights |
| Market risk |
Gradual erosion rather than automatic loss of all sales |
The key commercial date is therefore not a single exclusivity expiration date. The relevant question is when a biosimilar sponsor obtains approval, resolves patent disputes, and launches at a price that changes payer behavior.
What patent and regulatory barriers protect Cimzia?
Cimzia's protection is likely distributed across several patent categories:
- Composition-of-matter claims covering certolizumab-related antibody fragments or sequences.
- PEGylation and conjugation claims.
- Formulation claims covering concentration, stabilizers, pH and storage conditions.
- Manufacturing claims covering expression, purification and conjugation.
- Dosing and method-of-use claims for specific diseases or patient groups.
- Delivery-system patents covering prefilled syringes and autoinjectors.
A biologic's manufacturing process can create a meaningful barrier even when the central composition patent has expired. A biosimilar sponsor must demonstrate high similarity through analytical characterization, functional testing, pharmacokinetic studies and, where required, clinical evidence. Certolizumab's PEGylated Fab' structure adds analytical and manufacturing complexity compared with a conventional full-length monoclonal antibody.
What is the Orange Book status of Cimzia?
Cimzia is a biologic and is not protected through the traditional small-molecule Orange Book listing system. The relevant regulatory framework is the Public Health Service Act and the FDA's Purple Book, together with patent litigation under the Biologics Price Competition and Innovation Act.
This distinction matters for market-entry analysis. A biosimilar sponsor does not follow the same abbreviated new drug application and Paragraph IV process used for small molecules.
Are there Paragraph IV challenges or biosimilar lawsuits involving Cimzia?
Paragraph IV certifications apply to patents listed for small-molecule drugs in the Orange Book. They are not the standard mechanism for challenging a biologic such as Cimzia.
A certolizumab biosimilar applicant would generally use the BPCIA patent-exchange process, often called the "patent dance," followed by patent litigation if the reference-product sponsor asserts claims. Publicly disclosed information through the cited UCB reporting period did not identify an approved U.S. certolizumab biosimilar or a major publicly reported Cimzia biosimilar settlement.
The absence of an approved biosimilar does not remove future risk. Potential barriers include:
- Complexity of the PEGylated molecular structure.
- Limited commercial incentive compared with larger biologic markets.
- Cost of analytical and clinical development.
- Patent disputes involving formulation, manufacturing or device claims.
- Physician and payer preference for established TNF products.
- The possibility that newer IL-17, IL-23 or JAK therapies capture demand before a biosimilar launches.
What is Cimzia's FDA regulatory status?
Cimzia is FDA-approved for several chronic inflammatory diseases. Its core regulatory profile is mature, with the principal commercial opportunity coming from maintaining use in existing indications rather than adding a transformative new indication.
The product's regulatory strengths include:
- Multiple approved immune-mediated diseases.
- Established long-term safety data.
- Broad physician familiarity.
- A differentiated reproductive-health profile.
- Subcutaneous administration outside infusion centers.
The main regulatory and safety constraints are shared with the TNF class. These include serious infections, tuberculosis risk, malignancy warnings, hypersensitivity, demyelinating disease concerns, heart-failure considerations, and immunogenicity. Label requirements and class warnings limit the extent to which Cimzia can differentiate on safety alone.
What patent litigation and settlement risks affect Cimzia?
Cimzia's most important litigation risk is potential future biosimilar litigation rather than Paragraph IV litigation. A challenger could contest composition, formulation, manufacturing, dosing or device patents. UCB could seek damages, an injunction, or a negotiated launch date.
Potential settlement structures would include:
- Entry on a fixed date before the final patent expiry.
- Earlier entry in Europe than in the United States.
- A royalty-bearing license.
- Restrictions on interchangeable substitution.
- Separate settlements for different dosage forms or delivery systems.
No major publicly disclosed Cimzia biosimilar settlement was identified in the cited public sources through the UCB 2023 reporting period.
How strong is the Cimzia commercial and patent estate?
Cimzia has a medium-to-strong commercial estate but a weaker long-term growth profile than UCB's newer products.
| Factor |
Assessment |
| Revenue scale |
Strong, approximately €2 billion annually |
| Indication breadth |
Strong |
| Physician familiarity |
Strong |
| Pregnancy differentiation |
Strong but specialized |
| Class growth |
Mature |
| Patent durability |
Dependent on remaining secondary patents |
| Biosimilar vulnerability |
Moderate, increasing over time |
| Competitive intensity |
High |
| Manufacturing complexity |
Moderate to high |
| Long-term growth |
Low to moderate |
| Cash-flow value |
High |
The product's principal asset is its durable cash generation. Its principal weakness is that TNF inhibition is no longer the default growth segment in several indications. UCB must defend Cimzia through persistence, patient services, device convenience, and reproductive-health positioning while shifting future growth toward Bimzelx and other newer assets.
What generic or biosimilar launch scenarios exist for Cimzia?
A likely launch pattern would be gradual rather than immediate substitution across all markets.
Scenario 1: No near-term biosimilar launch
Cimzia remains protected by commercial complexity, patent disputes, and limited challenger economics. UCB preserves most revenue, with erosion caused mainly by payer pressure and newer biologics.
Scenario 2: One or more biosimilars launch in Europe first
European tendering could produce a faster price decline, especially in hospital or centralized procurement channels. UCB could retain physician preference in pregnancy-related use and in patients who are stable on treatment.
Scenario 3: U.S. biosimilar launch after patent settlement
A U.S. challenger could enter through a negotiated license. Initial erosion would depend on formulary placement, interchangeability, rebates and the level of discount. Commercial plans may favor the biosimilar for new starts while preserving Cimzia for existing patients.
Scenario 4: Multi-market competitive entry
Several biosimilars launch across the United States, Europe and other markets. This would create the greatest revenue risk, with net price compression, formulary exclusion risk and lower volume among treatment-naive patients.
What is the outlook for Cimzia's financial trajectory?
Cimzia is likely to move from mature growth into a stable or declining revenue phase as competition intensifies. UCB's near-term objective is to maximize the product's cash contribution, not to produce rapid unit growth.
The most important financial variables are:
- Net price after rebates.
- Share of new biologic starts.
- Persistence among existing patients.
- Use in Crohn's disease and axial spondyloarthritis.
- Pregnancy-related prescribing.
- U.S. payer positioning.
- Timing of any biosimilar launch.
- Internal substitution toward Bimzelx.
- European tender outcomes.
- Manufacturing and supply reliability.
Cimzia's revenue base gives UCB time to transition its immunology franchise. The product remains commercially valuable, but its valuation should reflect a mature biologic with expanding competitive risk rather than a growth-stage asset.
Key Takeaways
- Cimzia generated approximately €2 billion in annual sales by 2023 and remained one of UCB's principal products.
- Revenue grew at an estimated mid-single-digit rate from 2019 through 2023, but the product is entering a mature phase.
- The strongest differentiation is the Fc-free, PEGylated structure and limited placental transfer.
- Cimzia competes against TNF inhibitors, IL-17 and IL-23 biologics, JAK inhibitors, and UCB's own Bimzelx.
- U.S. biologic exclusivity expired in 2020. Patent, manufacturing and device rights remain relevant to launch timing.
- Paragraph IV litigation is not the appropriate framework because Cimzia is a biologic rather than an Orange Book small molecule.
- No approved U.S. certolizumab biosimilar or major publicly reported Cimzia biosimilar settlement was identified in the cited reporting period.
- The base financial case is durable cash generation with increasing risk of price and volume erosion.
- Bimzelx growth will determine whether UCB can replace Cimzia revenue as the older product loses momentum.
FAQs about certolizumab pegol market dynamics
Is Cimzia still a commercially important drug for UCB?
Yes. Cimzia remains a major UCB revenue contributor, generating approximately €2 billion annually by 2023 despite its mature lifecycle.
Does Cimzia have an advantage over Humira during pregnancy?
Cimzia's Fc-free structure results in limited placental transfer compared with full-length IgG antibodies. That profile is a key prescribing differentiator, although clinical choice depends on disease control, prior response, safety and physician judgment.
Can a certolizumab biosimilar receive automatic interchangeability in the United States?
Potentially, but the biosimilar sponsor would need to satisfy FDA requirements for interchangeability. Approval would not automatically force substitution in every payer or pharmacy setting.
Could Bimzelx cannibalize Cimzia sales?
Yes. Bimzelx can replace Cimzia in some psoriasis and psoriatic arthritis patients, but the two products also address different mechanisms and patient segments. Internal substitution is a strategic tradeoff for UCB.
Which Cimzia indication is most defensible against newer biologics?
Pregnancy-related use and selected rheumatoid arthritis, axial spondyloarthritis and Crohn's disease patients may be the most defensible segments. Plaque psoriasis is more exposed to IL-17 and IL-23 competition.
References
-
Clowse, M. E. B., Förger, F., Hwang, C., Thorp, J., Dolain, C., van de Venne, M., Lammerich, A., & Nakajima, A. (2017). Minimal to no transfer of certolizumab pegol into breast milk: Results from CRADLE, a prospective, postmarketing, multicenter pharmacokinetic study. Annals of the Rheumatic Diseases, 76(11), 1890-1896.
-
European Medicines Agency. (2024). Cimzia: EPAR product information. European Union.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Cimzia prescribing information. U.S. Department of Health and Human Services.
-
UCB. (2020). Annual report 2019. UCB S.A.
-
UCB. (2021). Annual report 2020. UCB S.A.
-
UCB. (2022). Annual report 2021. UCB S.A.
-
UCB. (2023). Annual report 2022. UCB S.A.
-
UCB. (2024). Annual report 2023. UCB S.A.
-
Mariette, X., Förger, F., Abraham, B., Flynn, A. D., Moltó, A., Flipo, R. M., van de Venne, M., Bérard, J. B., & Hovsepian, H. (2018). Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Annals of the Rheumatic Diseases, 77(2), 228-233.
